We haven't heard any more regarding the graphic in your post which states that Fuji will be starting P2 GvHD trials in late 2020.
I thought we may have had some feedback by now on ethics approval, trial approvals etc. for this trial. I have a theory now, that they are waiting on the MSB GvHD FDA approval (or not), before committing to a trial procedure. Any issues found by the FDA could be addressed in a tailored trial which addresses any questions raised.
It would be great to go head to head with an identical trial against the MSB technology. I was hoping this would be achieved with the COVID trial, but it would seem we limited ourselves geographically on this front.
The Cymerus Process, page-93
-
- There are more pages in this discussion • 31 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
27.0¢ |
Change
-0.005(1.82%) |
Mkt cap ! $48.78M | |||
| Open | High | Low | Value | Volume |
| 27.5¢ | 28.5¢ | 26.5¢ | $71.17K | 257.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 145786 | 27.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 28.0¢ | 15000 | 1 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| CYP (ASX) Chart |